Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX

Hsbc Holdings PLC raised its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 2,562.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,544,018 shares of the biopharmaceutical company’s stock after purchasing an additional 1,486,020 shares during the quarter. Hsbc Holdings PLC’s holdings in Royalty Pharma were worth $74,000,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of RPRX. LM Advisors LLC acquired a new position in shares of Royalty Pharma during the 4th quarter worth $26,000. Lloyd Advisory Services LLC. acquired a new stake in Royalty Pharma in the fourth quarter valued at about $30,000. Private Trust Co. NA boosted its stake in Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Blue Trust Inc. grew its position in Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 437 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 446 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling

In other Royalty Pharma news, CFO Terrance P. Coyne sold 64,399 shares of Royalty Pharma stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total transaction of $3,476,258.02. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total value of $8,160,000.00. Following the completion of the sale, the executive vice president owned 559,399 shares in the company, valued at $30,431,305.60. This trade represents a 21.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 427,800 shares of company stock valued at $23,333,723 in the last quarter. 18.84% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on RPRX. Morgan Stanley increased their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Weiss Ratings cut shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. UBS Group increased their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, TD Cowen boosted their target price on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $56.57.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $58.18 on Monday. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $59.44. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The company has a market cap of $33.50 billion, a PE ratio of 39.58, a P/E/G ratio of 10.30 and a beta of 0.43. The firm’s 50 day simple moving average is $55.01 and its 200 day simple moving average is $48.59.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.08. The firm had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. On average, research analysts anticipate that Royalty Pharma PLC will post 5.18 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, August 14th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.